News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
149,949 Results
Type
Article (5701)
Company Profile (107)
Press Release (144141)
Multimedia
Podcasts (41)
Webinars (9)
Section
Business (52698)
Career Advice (158)
Deals (9269)
Drug Delivery (75)
Drug Development (21383)
Employer Resources (31)
FDA (3368)
Job Trends (3874)
News (84798)
Policy (6517)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (10)
2024 BioMidwest Digital (8)
2024 Bio NC Digital (10)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Digital (7)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (9)
2024 Pharm Country Digital (3)
2026 BioCapital Standard (1)
Academia (405)
Accelerated approval (1)
Adcomms (8)
Allergies (31)
Alliances (6379)
ALS (37)
Alzheimer's disease (468)
Antibody-drug conjugate (ADC) (45)
Approvals (3378)
Artificial intelligence (68)
Autoimmune disease (5)
Automation (2)
Bankruptcy (64)
Best Places to Work (3544)
BIOSECURE Act (2)
Biosimilars (36)
Biotechnology (86)
Bladder cancer (30)
Brain cancer (10)
Breast cancer (97)
Cancer (682)
Cardiovascular disease (61)
Career advice (133)
Career pathing (6)
CAR-T (46)
Cell therapy (105)
Cervical cancer (8)
Clinical research (17906)
Collaboration (152)
Compensation (66)
Complete response letters (9)
COVID-19 (594)
CRISPR (12)
C-suite (18)
Cystic fibrosis (37)
Data (686)
Denatured (15)
Depression (16)
Diabetes (54)
Diagnostics (1769)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (8)
Drug discovery (20)
Drug pricing (44)
Drug shortages (9)
Duchenne muscular dystrophy (22)
Earnings (39256)
Editorial (1)
Employer branding (4)
Employer resources (22)
Events (23390)
Executive appointments (69)
FDA (3679)
Featured Employer (7)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (121)
Gene editing (27)
Generative AI (4)
Gene therapy (71)
GLP-1 (243)
Government (889)
Grass and pollen (2)
Guidances (27)
Healthcare (4827)
Huntington's disease (10)
IgA nephropathy (5)
Immunology and inflammation (20)
Indications (9)
Infectious disease (632)
Inflammatory bowel disease (49)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (18)
Interviews (18)
IPO (6069)
IRA (18)
Job creations (475)
Job search strategy (109)
Kidney cancer (7)
Labor market (13)
Layoffs (76)
Leadership (1)
Legal (1060)
Liver cancer (23)
Lung cancer (138)
Lymphoma (58)
Machine learning (2)
Management (5)
Manufacturing (67)
MASH (32)
Medical device (3697)
Medtech (3699)
Mergers & acquisitions (3366)
Metabolic disorders (224)
Multiple sclerosis (24)
NASH (17)
Neurodegenerative disease (20)
Neuropsychiatric disorders (4)
Neuroscience (645)
NextGen: Class of 2025 (992)
Non-profit (723)
Northern California (654)
Now hiring (17)
Obesity (117)
Opinion (70)
Ovarian cancer (20)
Pain (17)
Pancreatic cancer (30)
Parkinson's disease (59)
Partnered (1)
Patents (36)
Patient recruitment (20)
Peanut (20)
People (6975)
Pharmaceutical (15)
Pharmacy benefit managers (1)
Phase I (4941)
Phase II (7849)
Phase III (6739)
Pipeline (593)
Policy (33)
Postmarket research (633)
Preclinical (1548)
Press Release (24)
Prostate cancer (41)
Psychedelics (4)
Radiopharmaceuticals (152)
Rare diseases (103)
Real estate (743)
Recruiting (12)
Regulatory (4994)
Reports (15)
Research institute (417)
Resumes & cover letters (25)
Rett syndrome (3)
RNA editing (1)
RSV (19)
Schizophrenia (27)
Series A (22)
Series B (10)
Service/supplier (5)
Sickle cell disease (15)
Southern California (600)
Special edition (7)
Spinal muscular atrophy (36)
Sponsored (8)
Startups (391)
Stomach cancer (4)
Supply chain (13)
The Weekly (25)
United States (7379)
Vaccines (158)
Venture capitalists (6)
Weight loss (107)
Women's health (10)
Worklife (8)
Date
Today (34)
Last 7 days (116)
Last 30 days (673)
Last 365 days (9077)
2025 (2645)
2024 (19239)
2023 (20317)
2022 (11270)
2021 (11308)
2020 (10631)
2019 (9007)
2018 (6589)
2017 (6456)
2016 (5549)
2015 (6825)
2014 (4618)
2013 (3272)
2012 (3535)
2011 (4464)
2010 (4054)
Location
Africa (97)
Alabama (24)
Alaska (3)
Arizona (44)
Arkansas (5)
Asia (9242)
Australia (1383)
California (1521)
Canada (748)
China (128)
Colorado (101)
Connecticut (88)
Delaware (55)
Europe (20610)
Florida (224)
Georgia (54)
Idaho (25)
Illinois (113)
India (9)
Indiana (125)
Iowa (1)
Japan (55)
Kansas (30)
Kentucky (4)
Louisiana (6)
Maine (29)
Maryland (282)
Massachusetts (1487)
Michigan (127)
Minnesota (172)
Missouri (21)
Montana (19)
Nebraska (10)
Nevada (21)
New Hampshire (41)
New Jersey (650)
New Mexico (11)
New York (527)
North Carolina (503)
North Dakota (5)
Northern California (654)
Ohio (70)
Oklahoma (5)
Oregon (19)
Pennsylvania (506)
Puerto Rico (1)
Rhode Island (5)
South America (178)
South Carolina (3)
Southern California (600)
Tennessee (14)
Texas (265)
Utah (86)
Virginia (31)
Washington D.C. (10)
Washington State (221)
Wisconsin (14)
149,949 Results for "paragon 28".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Zimmer Biomet Completes Acquisition of Paragon 28
April 21, 2025
·
6 min read
Press Releases
Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28
January 28, 2025
·
13 min read
BioMidwest
Paragon 28 to Present at the Bank of America Securities 2024 Healthcare Conference
Paragon 28, Inc. announced that Albert DaCosta, Chairman and CEO, and Krissy Wright, Interim CFO, will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024, at 5:00 p.m. Pacific Time / 6:00 p.m. Mountain Time.
May 2, 2024
·
1 min read
Business
Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue guidance.
May 8, 2024
·
12 min read
Business
Paragon 28 To Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Paragon 28, Inc. announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024.
February 6, 2024
·
1 min read
BioMidwest
Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler® R3INFORCE™ Extraosseous Repair System
Paragon 28, Inc., is pleased to announce the launch of the Grappler® R3INFORCE™ Extraosseous Repair System designed to restore stability to the anterior and posterior ligaments surrounding the ankle during fibula fracture repairs and high ankle sprains.
March 28, 2024
·
5 min read
Business
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023
Paragon 28, Inc. today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023.
January 8, 2024
·
4 min read
Business
Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Net Revenue Guidance
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter and year ended December 31, 2023 and provided 2024 Net Revenue guidance.
February 29, 2024
·
15 min read
Business
Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024
Paragon 28, Inc. announced that Stephen Deitsch, Chief Financial Officer, has notified the Company of his intent to pursue an opportunity with OrganOx Limited, a commercial stage UK-based medical device company focused on therapeutic applications of isolated organ perfusion.
April 4, 2024
·
7 min read
BioMidwest
Paragon 28 Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures
Paragon 28, Inc. is proud to announce a novel solution in modernizing foot and ankle surgery with the launch of its FJ2000™ Power Console and Burr System designed for a wide range of minimally invasive and open procedures in the foot and ankle.
January 30, 2024
·
4 min read
1 of 14,995
Next
